Amir F. Heshmatpour Purchases 1,500 Shares of Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir F. Heshmatpour bought 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The stock was purchased at an average cost of $7.30 per share, with a total value of $10,950.00. Following the completion of the purchase, the president now directly owns 1,756,490 shares of the company’s stock, valued at $12,822,377. This represents a 0.09% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neonc Technologies Stock Down 0.8%

NASDAQ NTHI traded down $0.06 on Monday, hitting $7.43. 62,188 shares of the stock were exchanged, compared to its average volume of 85,148. Neonc Technologies Holdings, Inc. has a 52 week low of $4.11 and a 52 week high of $25.00.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Friday, May 9th. The company reported ($2.10) earnings per share for the quarter. The firm had revenue of $0.04 million for the quarter.

Hedge Funds Weigh In On Neonc Technologies

An institutional investor recently bought a new position in Neonc Technologies stock. HighPoint Advisor Group LLC acquired a new stake in Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 21,672 shares of the company’s stock, valued at approximately $290,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing.